RxCelerate took part in Rivus Pharmaceuticals’ $132m series B round while Bank of America and Citi backed AccessFintech’s $60m series C.

M&A

Nasdaq-listed bladder cancer drug developer Sesen Bio has agreed to merge with Carisma Therapeutics, a US-based immunotherapy developer backed by pharmaceutical groups Penn Medicine, Merck & Co, Livzon Pharmaceutical and AbbVie. The combined business will receive $30m in financing from AbbVie, Penn Medicine, Merck’s MRL Ventures Fund, Livzon, HealthCap, Wellington Partners, SymBiosis, TPG Biotech, Agent Capital, Solasta, Pictet Alternative Advisors and 4Bio concurrent to the deal.

Bankruptcy

Compute North, a US-based crypto mining and infrastructure platform that…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn